Pediatric Behçet’s disease: Experience of a single tertiary center

Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 ye...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of rheumatology 2023-06, Vol.38 (2), p.282-290
Hauptverfasser: Acari, Ceyhun, Isguder, Rana, Torun, Ruya, Makay, Balahan, Unsal, Sevket Erbil
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 290
container_issue 2
container_start_page 282
container_title Archives of rheumatology
container_volume 38
creator Acari, Ceyhun
Isguder, Rana
Torun, Ruya
Makay, Balahan
Unsal, Sevket Erbil
description Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behcet's Disease (ICBD), and PEDBD criteria. Results: The mean age at diagnosis was 12.6 [+ or -] 3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8 [+ or -] 2.9 years. The mean follow-up period was 31.9 [+ or -] 20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)- B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. Conclusion: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Keywords: Diagnostic criteria, HLA-B51, pathergy, Pediatric Behcet's disease.
doi_str_mv 10.46497/ArchRheumatol.2023.9651
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10481698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A754111759</galeid><sourcerecordid>A754111759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-eb3afa9f280c1727e1398d228b2a4a914cab8ab7564cb90a70b9323db4fb3afc3</originalsourceid><addsrcrecordid>eNptkdFqFDEUhgdRsLR9h4Dg3axJJpNJvCnbsmqhYBG9DmcyZ3ZSZibbJFPqna_hE_ggvolPYtYW64LkIofk-_9zkr8oCKMrIYVu3qyDHT4NuEyQ_LjilFcrLWv2rDjikqlS1pQ-zzUTqqypkC-L0xhvKKVMNFLS6qjYXGPnIAVnyTkOP39g-vXteySdiwgR35LN_Q6Dw9ki8T0BEt28HZEkDMlB-Eoszrk-KV70MEY8fdyPiy_vNp8vPpRXH99fXqyvSiukTiW2FfSge66oZQ1vkFVadZyrloMAzYSFVkHb1FLYVlNoaKsrXnWt6PdKWx0XZw--u6WdsNs3DzCaXXBTHsZ4cObwZnaD2fo7w6hQTGqVHV49OgR_u2BM5sYvYc5DG664zn_KFXuitjCicXPvs5udXLRm3dSCMdbUOlOr_1B5dTg562fsXT4_ELz-RzAgjGmIflyS83M8BNUDaIOPMWD_94mMmj_Jm4PkzT55s0---g3MFqYt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829497281</pqid></control><display><type>article</type><title>Pediatric Behçet’s disease: Experience of a single tertiary center</title><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Acari, Ceyhun ; Isguder, Rana ; Torun, Ruya ; Makay, Balahan ; Unsal, Sevket Erbil</creator><creatorcontrib>Acari, Ceyhun ; Isguder, Rana ; Torun, Ruya ; Makay, Balahan ; Unsal, Sevket Erbil</creatorcontrib><description>Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behcet's Disease (ICBD), and PEDBD criteria. Results: The mean age at diagnosis was 12.6 [+ or -] 3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8 [+ or -] 2.9 years. The mean follow-up period was 31.9 [+ or -] 20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)- B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. Conclusion: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Keywords: Diagnostic criteria, HLA-B51, pathergy, Pediatric Behcet's disease.</description><identifier>ISSN: 2148-5046</identifier><identifier>ISSN: 1309-0291</identifier><identifier>EISSN: 2618-6500</identifier><identifier>EISSN: 1309-0283</identifier><identifier>DOI: 10.46497/ArchRheumatol.2023.9651</identifier><language>eng</language><publisher>Istanbul: Turkish League Against Rheumatism</publisher><subject>Adalimumab ; Age ; Antigens ; Cerebrospinal fluid ; Children ; Diseases ; Erythema ; Females ; Histocompatibility antigens ; HLA histocompatibility antigens ; Laboratories ; Leukocytes ; Lupus ; Males ; Medical research ; Medicine, Experimental ; Mutation ; Nervous system ; Original ; Patients ; Pediatrics ; Skin ; Statistical analysis ; Thrombosis ; Ulcers ; Vein &amp; artery diseases</subject><ispartof>Archives of rheumatology, 2023-06, Vol.38 (2), p.282-290</ispartof><rights>COPYRIGHT 2023 Turkish League Against Rheumatism</rights><rights>Copyright Prof Sebnem Ataman, President Turkish League Against Rheumatism 2023</rights><rights>Copyright © 2023, Turkish League Against Rheumatism 2023 Turkish League Against Rheumatism</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c469t-eb3afa9f280c1727e1398d228b2a4a914cab8ab7564cb90a70b9323db4fb3afc3</cites><orcidid>0000-0002-6070-8196 ; 0000-0002-4044-1471 ; 0000-0002-8800-0800 ; 0000-0002-7175-0015 ; 0000-0001-6193-0402</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481698/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481698/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Acari, Ceyhun</creatorcontrib><creatorcontrib>Isguder, Rana</creatorcontrib><creatorcontrib>Torun, Ruya</creatorcontrib><creatorcontrib>Makay, Balahan</creatorcontrib><creatorcontrib>Unsal, Sevket Erbil</creatorcontrib><title>Pediatric Behçet’s disease: Experience of a single tertiary center</title><title>Archives of rheumatology</title><description>Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behcet's Disease (ICBD), and PEDBD criteria. Results: The mean age at diagnosis was 12.6 [+ or -] 3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8 [+ or -] 2.9 years. The mean follow-up period was 31.9 [+ or -] 20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)- B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. Conclusion: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Keywords: Diagnostic criteria, HLA-B51, pathergy, Pediatric Behcet's disease.</description><subject>Adalimumab</subject><subject>Age</subject><subject>Antigens</subject><subject>Cerebrospinal fluid</subject><subject>Children</subject><subject>Diseases</subject><subject>Erythema</subject><subject>Females</subject><subject>Histocompatibility antigens</subject><subject>HLA histocompatibility antigens</subject><subject>Laboratories</subject><subject>Leukocytes</subject><subject>Lupus</subject><subject>Males</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mutation</subject><subject>Nervous system</subject><subject>Original</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Skin</subject><subject>Statistical analysis</subject><subject>Thrombosis</subject><subject>Ulcers</subject><subject>Vein &amp; artery diseases</subject><issn>2148-5046</issn><issn>1309-0291</issn><issn>2618-6500</issn><issn>1309-0283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkdFqFDEUhgdRsLR9h4Dg3axJJpNJvCnbsmqhYBG9DmcyZ3ZSZibbJFPqna_hE_ggvolPYtYW64LkIofk-_9zkr8oCKMrIYVu3qyDHT4NuEyQ_LjilFcrLWv2rDjikqlS1pQ-zzUTqqypkC-L0xhvKKVMNFLS6qjYXGPnIAVnyTkOP39g-vXteySdiwgR35LN_Q6Dw9ki8T0BEt28HZEkDMlB-Eoszrk-KV70MEY8fdyPiy_vNp8vPpRXH99fXqyvSiukTiW2FfSge66oZQ1vkFVadZyrloMAzYSFVkHb1FLYVlNoaKsrXnWt6PdKWx0XZw--u6WdsNs3DzCaXXBTHsZ4cObwZnaD2fo7w6hQTGqVHV49OgR_u2BM5sYvYc5DG664zn_KFXuitjCicXPvs5udXLRm3dSCMdbUOlOr_1B5dTg562fsXT4_ELz-RzAgjGmIflyS83M8BNUDaIOPMWD_94mMmj_Jm4PkzT55s0---g3MFqYt</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Acari, Ceyhun</creator><creator>Isguder, Rana</creator><creator>Torun, Ruya</creator><creator>Makay, Balahan</creator><creator>Unsal, Sevket Erbil</creator><general>Turkish League Against Rheumatism</general><general>Prof Sebnem Ataman, President Turkish League Against Rheumatism</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6070-8196</orcidid><orcidid>https://orcid.org/0000-0002-4044-1471</orcidid><orcidid>https://orcid.org/0000-0002-8800-0800</orcidid><orcidid>https://orcid.org/0000-0002-7175-0015</orcidid><orcidid>https://orcid.org/0000-0001-6193-0402</orcidid></search><sort><creationdate>20230601</creationdate><title>Pediatric Behçet’s disease: Experience of a single tertiary center</title><author>Acari, Ceyhun ; Isguder, Rana ; Torun, Ruya ; Makay, Balahan ; Unsal, Sevket Erbil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-eb3afa9f280c1727e1398d228b2a4a914cab8ab7564cb90a70b9323db4fb3afc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adalimumab</topic><topic>Age</topic><topic>Antigens</topic><topic>Cerebrospinal fluid</topic><topic>Children</topic><topic>Diseases</topic><topic>Erythema</topic><topic>Females</topic><topic>Histocompatibility antigens</topic><topic>HLA histocompatibility antigens</topic><topic>Laboratories</topic><topic>Leukocytes</topic><topic>Lupus</topic><topic>Males</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mutation</topic><topic>Nervous system</topic><topic>Original</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Skin</topic><topic>Statistical analysis</topic><topic>Thrombosis</topic><topic>Ulcers</topic><topic>Vein &amp; artery diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Acari, Ceyhun</creatorcontrib><creatorcontrib>Isguder, Rana</creatorcontrib><creatorcontrib>Torun, Ruya</creatorcontrib><creatorcontrib>Makay, Balahan</creatorcontrib><creatorcontrib>Unsal, Sevket Erbil</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Acari, Ceyhun</au><au>Isguder, Rana</au><au>Torun, Ruya</au><au>Makay, Balahan</au><au>Unsal, Sevket Erbil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pediatric Behçet’s disease: Experience of a single tertiary center</atitle><jtitle>Archives of rheumatology</jtitle><date>2023-06-01</date><risdate>2023</risdate><volume>38</volume><issue>2</issue><spage>282</spage><epage>290</epage><pages>282-290</pages><issn>2148-5046</issn><issn>1309-0291</issn><eissn>2618-6500</eissn><eissn>1309-0283</eissn><abstract>Objectives: The aim of this study was to examine the clinical and phenotypic features of pediatric Behcet's disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. Patients and methods: Thirty-four patients (20 males, 14 females; mean age: 16.0 [+ or -] 2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behcet's Disease (ICBD), and PEDBD criteria. Results: The mean age at diagnosis was 12.6 [+ or -] 3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8 [+ or -] 2.9 years. The mean follow-up period was 31.9 [+ or -] 20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)- B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. Conclusion: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Keywords: Diagnostic criteria, HLA-B51, pathergy, Pediatric Behcet's disease.</abstract><cop>Istanbul</cop><pub>Turkish League Against Rheumatism</pub><doi>10.46497/ArchRheumatol.2023.9651</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6070-8196</orcidid><orcidid>https://orcid.org/0000-0002-4044-1471</orcidid><orcidid>https://orcid.org/0000-0002-8800-0800</orcidid><orcidid>https://orcid.org/0000-0002-7175-0015</orcidid><orcidid>https://orcid.org/0000-0001-6193-0402</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2148-5046
ispartof Archives of rheumatology, 2023-06, Vol.38 (2), p.282-290
issn 2148-5046
1309-0291
2618-6500
1309-0283
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10481698
source PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Adalimumab
Age
Antigens
Cerebrospinal fluid
Children
Diseases
Erythema
Females
Histocompatibility antigens
HLA histocompatibility antigens
Laboratories
Leukocytes
Lupus
Males
Medical research
Medicine, Experimental
Mutation
Nervous system
Original
Patients
Pediatrics
Skin
Statistical analysis
Thrombosis
Ulcers
Vein & artery diseases
title Pediatric Behçet’s disease: Experience of a single tertiary center
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T20%3A24%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pediatric%20Beh%C3%A7et%E2%80%99s%20disease:%20Experience%20of%20a%20single%20tertiary%20center&rft.jtitle=Archives%20of%20rheumatology&rft.au=Acari,%20Ceyhun&rft.date=2023-06-01&rft.volume=38&rft.issue=2&rft.spage=282&rft.epage=290&rft.pages=282-290&rft.issn=2148-5046&rft.eissn=2618-6500&rft_id=info:doi/10.46497/ArchRheumatol.2023.9651&rft_dat=%3Cgale_pubme%3EA754111759%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2829497281&rft_id=info:pmid/&rft_galeid=A754111759&rfr_iscdi=true